Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
Crossref DOI link: https://doi.org/10.1038/nn.4508
Published Online: 2017-02-13
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Corey, David R
Text and Data Mining valid from 2017-02-13
Article History
First Online: 13 February 2017
Competing interests
: D.R.C. receives licensing income from Ionis Pharmaceuticals for an unrelated discovery.